Literature DB >> 8425693

Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction.

M Pera1, A J Cameron, V F Trastek, H A Carpenter, A R Zinsmeister.   

Abstract

BACKGROUND: The aim of this study was to determine whether the incidence of adenocarcinoma of the esophagus and esophagogastric junction in a well-defined population was higher than previously recognized.
METHODS: Clinical records and original histological slides from patients residing in Olmsted County, Minnesota, were reviewed and compared with a previous study in the same population.
RESULTS: The incidence of esophageal adenocarcinoma rose from 0.13 for 1935-1971 to 0.74 for 1974-1989, and the incidence of adenocarcinoma of the esophagogastric junction rose from 0.25 to 1.34 per 100,000 person-years. Histological review of preserved surgical specimens showed associated intestinal metaplasia (Barrett's esophagus) in 2 of 2 esophageal and in 5 of 9 esophagogastric adenocarcinomas.
CONCLUSIONS: The incidence of adenocarcinoma in each location increased five to sixfold compared with the earlier study. This increase could not be explained by improved diagnostic methods or classification changes. The association with Barrett's esophagus and the parallel increased incidence of cancer in each location is evidence that adenocarcinoma of the esophagus and of the esophagogastric junction are related disorders.

Entities:  

Mesh:

Year:  1993        PMID: 8425693     DOI: 10.1016/0016-5085(93)90420-h

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  173 in total

1.  Proton pump inhibitors for Barrett's oesophagus.

Authors:  G Triadafilopoulos
Journal:  Gut       Date:  2000-02       Impact factor: 23.059

2.  Gastroesophageal reflux and Helicobacter pylori: a review.

Authors:  F Pace; G Bianchi Porro
Journal:  World J Gastroenterol       Date:  2000-06       Impact factor: 5.742

3.  The phenotype of gastric mucosa coexisting with Barrett's oesophagus.

Authors:  M Rugge; V Russo; G Busatto; R M Genta; F Di Mario; F Farinati; D Y Graham
Journal:  J Clin Pathol       Date:  2001-06       Impact factor: 3.411

4.  Combination of endoscopic argon plasma coagulation and antireflux surgery for treatment of Barrett's esophagus.

Authors:  H Tigges; K H Fuchs; J Maroske; M Fein; S M Freys; J Müller; A Thiede
Journal:  J Gastrointest Surg       Date:  2001 May-Jun       Impact factor: 3.452

Review 5.  Endoscopic ablation of Barrett's esophagus.

Authors:  M B Fennerty
Journal:  Curr Gastroenterol Rep       Date:  1999-06

6.  Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma.

Authors:  J W van Sandick; J J van Lanschot; B W Kuiken; G N Tytgat; G J Offerhaus; H Obertop
Journal:  Gut       Date:  1998-08       Impact factor: 23.059

7.  Time gated fluorescence spectroscopy in Barrett's oesophagus.

Authors:  M-A E J Ortner; B Ebert; E Hein; K Zumbusch; D Nolte; U Sukowski; J Weber-Eibel; B Fleige; M Dietel; M Stolte; G Oberhuber; R Porschen; B Klump; H Hörtnagl; H Lochs; H Rinneberg
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

8.  Correlation between endoscopic macroscopic type and invasion depth for early esophagogastric junction adenocarcinomas.

Authors:  Ichiro Oda; Seiichiro Abe; Chika Kusano; Haruhisa Suzuki; Satoru Nonaka; Shigetaka Yoshinaga; Hirokazu Taniguchi; Tadakazu Shimoda; Takuji Gotoda
Journal:  Gastric Cancer       Date:  2011-01-28       Impact factor: 7.370

9.  Use of methylene blue for detection of specialized intestinal metaplasia in GERD patients presenting for screening upper endoscopy.

Authors:  Marten B Duncan; J David Horwhat; Corrinne L Maydonovitch; Ferdanando Ramos; Ramon Colina; Erich Gaertner; Hyun Yang; Roy K H Wong
Journal:  Dig Dis Sci       Date:  2005-02       Impact factor: 3.199

Review 10.  Carcinoma of the gastroesophageal junction in Chinese patients.

Authors:  Qin Huang
Journal:  World J Gastroenterol       Date:  2012-12-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.